Titre : Shortened Therapy of Eight Weeks With Paritaprevir/ritonavir/Ombitasvir and Dasabuvir Is Highly Effective in People With Recent HCV Genotype 1 Infection
link : Shortened Therapy of Eight Weeks With Paritaprevir/ritonavir/Ombitasvir and Dasabuvir Is Highly Effective in People With Recent HCV Genotype 1 Infection
Shortened Therapy of Eight Weeks With Paritaprevir/ritonavir/Ombitasvir and Dasabuvir Is Highly Effective in People With Recent HCV Genotype 1 Infection
Is an 8-week therapy of paritaprevir/ritonavir/ombitasvir and dasabuvir + ribavirin as effective as the standard 12-week regimen in individuals with recent HCV infection?October 17, 2018
Articles Available on Medscape
J Viral Hepat. 2018;25(10):1180-1188. and dasabuvir
Paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin for 12 weeks are approved for treatment of chronic HCV genotype 1 infection. This study assessed the efficacy of shortened duration paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin for 8 weeks among people with recent HCV infection. In this open-label single-arm trial conducted in Australia, England and New Zealand, adults with recent HCV (duration of infection <12 months) received paritaprevir/ritonavir/ombitasvir and dasabuvir (with weight-based ribavirin for genotypes 1a and 1, no subtype) for 8 weeks. The primary endpoint was sustained virological response at 12 weeks post-treatment (SVR12) in the intention-to-treat (ITT) population. Thirty people (median age 38 years, male 93%) commenced treatment (with ribavirin, 97%), of whom 77% (n = 23) were HIV-positive, 93% (n = 28) had genotype 1a infection and 53% (n = 16) had ever injected drugs. Median maximum ALT in the preceding 12 months was 433 IU/L (IQR 321, 1012). Acute clinical hepatitis with ALT > 10 x ULN was documented in 83% (n = 25); one participant (3%) had jaundice. At baseline, median estimated duration of infection was 30 weeks (range 11, 51), and median HCV RNA was 5.7 log10 IU/mL (range 2.7, 7.3). SVR12 was achieved in 97% (29/30; early discontinuation at week 2, n = 1; per protocol 100%, 29/29). No relapse or reinfection was observed. In conclusion, paritaprevir/ritonavir/ombitasvir and dasabuvir (with ribavirin) for eight weeks were highly effective among HIV-positive and HIV-negative individuals with recent HCV infection. These data support the use of this shortened duration direct-acting antiviral regimen in this population.
Read the full-text article: http://www.medscape.com/viewarticle/902923
Free registration may be required
Thus articles Shortened Therapy of Eight Weeks With Paritaprevir/ritonavir/Ombitasvir and Dasabuvir Is Highly Effective in People With Recent HCV Genotype 1 Infection
that is all articles Shortened Therapy of Eight Weeks With Paritaprevir/ritonavir/Ombitasvir and Dasabuvir Is Highly Effective in People With Recent HCV Genotype 1 Infection This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article Shortened Therapy of Eight Weeks With Paritaprevir/ritonavir/Ombitasvir and Dasabuvir Is Highly Effective in People With Recent HCV Genotype 1 Infection the link address https://newsaninpiration.blogspot.com/2018/10/shortened-therapy-of-eight-weeks-with.html
0 Response to "Shortened Therapy of Eight Weeks With Paritaprevir/ritonavir/Ombitasvir and Dasabuvir Is Highly Effective in People With Recent HCV Genotype 1 Infection"
Post a Comment